Saturday 17 October 2026 Export KALA’s income statement to Excel — free account

KALA BIO, Inc.

KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.

0.19 0.00 0.00%

Follow KALA

Alert me

Market cap: $3.7M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: 3/9
Altman Z: −11.18
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3.72

Revenue 5.75

Net Income (10.08)

Free Cash Flow (19.86)

Net Debt (7.23)

Current Ratio 6.88

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.77)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 56.16%

Next Y EPS Growth 88.09%

Next Y revenue growth (57.09%)

Next 5Y EPS Growth 65.97%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

P/B against its own 10 years 0.15%

10-year low 10-year high

EV/Sales against its own 10 years 51.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	51	51	8	7
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	53	53	9	11

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	10	—	—
Other	—	—	—	—
	8	17	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(13.79%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(41.25%)	(28.29%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	1	2	0	—	4
’21	3	3	3	2	11
’20	1	1	2	2	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(9)	(8)	(11)	(5)	(32)
’24	(11)	(9)	(5)	(5)	(29)
’23	(10)	(8)	(3)	(8)	(28)
’22	(24)	(25)	(16)	(14)	(79)
’21	(33)	(22)	(26)	(28)	(108)
’20	(20)	(19)	(26)	(26)	(91)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(9)	(8)	(11)	(5)	(32)
’24	(11)	(9)	(5)	(5)	(30)
’23	(10)	(8)	(3)	(8)	(28)
’22	(24)	(26)	(16)	(14)	(79)
’21	(33)	(22)	(26)	(28)	(109)
’20	(20)	(20)	(26)	(26)	(93)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.14)	(21.32)	—	—	—
’25	(70.50)	(85.50)	(53.50)	43.00	(165.50)
’24	(210.00)	(158.00)	(96.50)	(87.00)	(507.50)
’23	(349.50)	(218.00)	(170.50)	(159.00)	(867.50)
’22	(1.12k)	(950.00)	962.50	(398.50)	(1.47k)
’21	(1.22k)	(1.42k)	(1.07k)	(1.70k)	(5.47k)
’20	(1.35k)	(1.05k)	(1.25k)	(1.37k)	(4.97k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	33,775.00	10,075.00	8,100.00	9,200.00	2,775.00	177.20	255.00	210.50	25.50	Analyst estimates 2026–2028 Powerpack
	High	—	66,875.00	50,425.00	23,125.00	36,700.00	24,922.50	4,850.00	2,836.00	462.50	1,030.00
People
People	Employees	25	37	130	136	188	192	34	43	38	6
	Revenue/emp, $m	0.00	0.00	0.00	0.04	0.03	0.06	0.11	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	6	6	11	4	—	—	—
	Gross margin, %	0.00	0.00	0.00	66.94	50.13	63.55	34.22	—	—	—
	EBT	(33)	(42)	(67)	(94)	(104)	(143)	(45)	(42)	(39)	(27)
	EBT margin, %	0.00	0.00	0.00	(1,553.29)	(1,639.85)	(1,268.73)	(1,151.64)	0.00	0.00	0.00
	Net income	(33)	(42)	(67)	(94)	(104)	(143)	(45)	(42)	(39)	(27)
	Depreciation	0	1	1	2	2	2	2	2	2	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	443.36	302.95	427.38	128.03	0.00	0.00	0.00
	Earnings	(70,209.57)	(9,277.14)	(6,225.00)	(6,900.00)	(4,975.00)	(5,475.00)	(1,474.00)	(867.50)	(507.50)	(165.50)
	Cash flow	(54,696.00)	(7,412.61)	(5,058.04)	(6,767.88)	(4,318.76)	(4,115.40)	(2,595.66)	(574.63)	(387.11)	(196.26)
	Capex	(306.00)	(104.35)	(147.48)	(97.45)	(92.48)	(30.19)	(6.55)	(11.58)	(2.74)	(0.09)
	Free cash flow	(55,002.00)	(7,516.96)	(5,205.51)	(6,865.33)	(4,411.24)	(4,145.59)	(2,602.20)	(586.21)	(389.86)	(196.36)
	Book value	61,258.00	19,495.43	9,811.03	2,167.30	4,761.67	638.94	624.14	154.40	162.48	42.92
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	P/S	—	—	—	20.81	55.95	7.08	8.45	—	—	—
	P/B	—	—	—	4.26	3.56	4.73	2.56	—	—	—
	EV/Sales	—	—	—	18.68	43.41	7.19	5.21	—	—	—
	EV/FCF	—	—	—	(1.21)	(2.98)	(0.74)	(0.38)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(27)	(34)	(54)	(93)	(91)	(108)	(79)	(28)	(29)	(32)
	Capex	0	0	(2)	(1)	(2)	(1)	0	(1)	0	0
	Free cash flow	(28)	(35)	(56)	(94)	(93)	(109)	(79)	(28)	(30)	(32)
Balance, $m
Balance, $m	Working capital	40	100	160	81	149	87	60	45	36	7
	Total debt	10	19	71	73	74	95	52	38	35	—
	Net debt	(36)	(96)	(100)	(13)	(80)	1	(19)	(13)	(16)	(8)
	Shareholders’ equity	31	90	105	30	100	17	19	8	12	7
Returns, %
Returns, %	ROA	(143.18)	(51.83)	(39.55)	(50.28)	(55.50)	(79.00)	(39.62)	(59.12)	(69.12)	(83.05)
	ROIC	0.00	0.00	(848.20)	(329.12)	(297.33)	(449.62)	(13,403.22)	0.00	0.00	0.00
	ROE	(3,460.30)	(4,403.86)	(68.57)	(140.12)	(160.89)	(244.19)	(250.56)	(318.75)	(388.29)	(279.19)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Sep 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OSRH OSR Health, Inc.	$4.1M	— (loss-making)	—	−72.20% (below 0%: shrinking)	n/m	−398.76% (below 0%: shrinking)	27.43%	(960.69%)	Compare
PMCB Nuvilex Inc.	$3.8M	— (loss-making)	—	−103.94% (below 0%: shrinking)	n/m	+60.84% (above 0%: growing)	100.00%	0.00%	Compare
KALA KALA BIO, Inc.	$3.7M	— (loss-making)	— (loss-making)	−86.31% (below 0%: shrinking)	n/m	+80.19% (above 0%: growing)	0.00%	0.00%
ERNA Ernexa Therapeutics Inc.	$3.5M	— (loss-making)	— (loss-making)	−94.12% (below 0%: shrinking)	n/m	−64.10% (below 0%: shrinking)	100.00%	0.00%	Compare
PPCB Propanc Biopharma Inc	$3.5M	— (loss-making)	—	—	−99.64% (below 0%: shrinking)	−1,637.42% (below 0%: shrinking)	—	0.00%	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.5M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%	Compare
IOBTQ IO Biotech, Inc.	$3.5M	— (loss-making)	—	—	n/m	+11.22% (above 0%: growing)	0.00%	0.00%	Compare
UNBX UNITY Biotechnology, Inc.	$3.4M	— (loss-making)	— (loss-making)	—	n/m	−23.10% (below 0%: shrinking)	0.00%	0.00%	Compare
LIPO Lipella Pharmaceuticals Inc.	$3.4M	— (loss-making)	— (loss-making)	−36.44% (below 0%: shrinking)	n/m	−41.79% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$3.5M	—	—	−83.16%	—	−32.44%	27.43%	0.00%

All 614 Biotechnology stocks →

KALA BIO, Inc. (KALA) key facts

KALA BIO, Inc. (KALA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million.
As of October 16, 2026, KALA traded at $0.19, a market capitalization of $3.7 million.
Return on equity was −279.2% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −11.18 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.